- Alvotech and U.S. commercial partner Teva have signed a “long-term agreement” with an unspecified company to boost access to their biosimilar version of AbbVie’s blockbuster drug Humira, Alvotech said Friday. An Alvotech spokesperson declined to provide specifics.
- The deal comes seven weeks after the Food and Drug Administration…
Click here to view original postClick Here to Publish/Feature Your Company or Product News with Biotech Networks
